Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FPR2 | P25090 | 15/20 | 0.46 |
| ▸ | FPR3 | P25089 | 12/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14253879 | 0.75 | ABL1 (0.53) | CCNE1CDK2CDK5ATAD2 | |
| SCHEMBL962327 | 0.73 | CNR2 (0.53) | — | |
| SCHEMBL4827961 | 0.73 | LMNA (0.53) | SMN1; SMN2 | |
| SCHEMBL6729 | 0.72 | CCNE1 (0.59) | MAPK10SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL12046973 | 0.71 | GAA (0.56) | MAPK10SMN1; SMN2 | |
| SCHEMBL4827968 | 0.71 | ABL1 (0.48) | SMN1; SMN2CCNE1CDK2CDK5ATAD2 | |
| SCHEMBL14476229 | 0.71 | SMN1; SMN2 (0.55) | MAPK10SMN1; SMN2FPR2FPR3CCNE1 | |
| SCHEMBL1749806 | 0.71 | SMN1; SMN2 (0.59) | MAPK10SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL20270816 | 0.70 | SMN1; SMN2 (0.58) | MAPK10SMN1; SMN2FPR2FPR3CCNE1 | |
| SCHEMBL1053446 | 0.70 | ADORA1 (0.49) | MAPK10SMN1; SMN2FPR2FPR3CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348425-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2007092000-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-1776368-A1 | INHIBITORS OF HCV REPLICATION | Bristol-Myers Squibb Company (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7153848-B2 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060166964-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| US-20060046983-A1 | Inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-02 | — | — | US | disclosed |
| WO-2006020082-A1 | INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166964-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | MAPK10 3295/4885SMN1; SMN2 4394/4885FPR2 4184/4885 |
| US-20060046983-A1 | Inhibitors of HCV replication | EIF2AK2, HCCS, IDO1 | MAPK10 3295/4885SMN1; SMN2 4394/4885FPR2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.